A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis
This research study is looking into a new medication called upadacitinib for a condition called giant cell arteritis (GCA). GCA is a condition where blood vessels become inflamed. The study aims to find out if upadacitinib can effectively help people with GCA stay in remission (meaning their symptoms are under control) for a full year. It also wants to see if this new medicine can help reduce the amount of steroid medication (like Prednisolone) that people need to take. Half the participants will receive the new medicine, while the other half will get a dummy medicine, to fairly compare the effects. Researchers will be looking at how well people's symptoms are managed and how many steroids they need.
At a glance
What is this study about?
Giant cell arteritis (GCA) is a condition that causes swelling and tenderness in your arteries, often in your head. This can lead to headaches, jaw pain, vision problems, and other serious issues. Currently, steroid medicines like prednisolone are the main treatment. While these can be very effective, taking steroids for a long time can lead to unwanted side effects.
This study, called a Phase 3 trial, is a big step in researching a new medicine called upadacitinib. Researchers want to see if this new medicine could be another option for people with GCA. The main goal is to find out if upadacitinib can help people stay free of GCA symptoms for a whole year while also allowing them to gradually reduce their steroid medication. This would mean fewer side effects from long-term steroid use.
To make sure the results are fair and accurate, some people in the study will receive upadacitinib, and others will receive a dummy medicine (placebo), along with their regular steroid treatment. Neither the patients nor their doctors will know who is getting which treatment. Researchers will carefully monitor how well people are doing, how many steroids they need, and their overall quality of life, to see if upadacitinib makes a real difference.
Key takeaways
- This study is testing a new medicine for giant cell arteritis (GCA).
- It aims to see if the new medicine can help manage GCA and reduce steroid use.
- Participants will receive either the new medicine or a dummy medicine.
- The study lasts about a year and involves regular check-ups.
- It's a Phase 3 trial, meaning it's a key stage in testing new treatments.
Who may be eligible?
To join this study, you must be at least 18 years old. Both men and women are welcome to take part. The study is specifically for people who have been diagnosed with giant cell arteritis (GCA).
If you're interested in potentially joining, the study doctor will go through a full check-up to make sure this study is right for you and that you meet all the specific health requirements. These checks help to keep you safe and make sure the study gathers useful and clear information.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with giant cell arteritis (GCA)?
- Are you able to attend regular clinic appointments for about a year?
- Are you willing to take the study medication (or dummy medicine) as instructed?
- Are you willing to follow a plan to reduce your steroid medication?
What does participation involve?
If you decide to take part in this study, you would be involved for about a year (52 weeks). You'd have regular visits to the clinic where you would have check-ups and assessments. These visits would involve discussing your symptoms, having blood tests, and perhaps other tests to monitor your GCA.
You would take either the study medicine (upadacitinib) or a dummy medicine, along with a carefully planned, reducing dose of your steroid medication. It's important to stick to this medicine schedule. The research team will track how your GCA symptoms are doing, how many steroids you're taking, and how you feel generally, including your energy levels and quality of life.
Potential risks and benefits
Locations (10)
- —UnverifiedDenmark
- —UnverifiedBelgium
- —UnverifiedGermany
- —UnverifiedGreece
- —UnverifiedSweden
- —UnverifiedSpain
- —UnverifiedPortugal
- —UnverifiedFrance
- —UnverifiedNetherlands
- —UnverifiedHungary
Common questions
What is giant cell arteritis (GCA)?
GCA is a condition where the blood vessels, often in your head, become inflamed. This can cause headaches, jaw pain, and vision problems.
What is upadacitinib?
Upadacitinib is a new medicine being tested to see if it can help treat GCA.
What does 'placebo-controlled' mean?
It means some people will get the active medicine, and others will get a dummy pill (placebo) that looks the same but has no medicine in it, to fairly compare effects.
Will I still take my steroid medicine?
Yes, you will continue to take your steroid medicine, but the study will look at whether you can gradually reduce the dose.
How long will the study last for me?
If you join, your participation in the study would last for about 52 weeks, which is just under a year.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.